Anne Peters, MD
Internal Medicine · Los Angeles, CANPI 1023156296
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,750 of the $6,170 with a category attached, or 60.8%. Zealand Pharma A/s accounts for 60.8% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2020 at $4,834 and has fallen 93.4% since, to $318 in 2021. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $57.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zealand Pharma A/s$4K
- Amgen$405
- Astellas Pharma US Inc$192
- AbbVie$173
- Novo Nordisk$171
- Mannkind Corporation$165
- plus $1K from 27 others
Across 11 payments — averaging $24,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insulet Corporation$263K
- Sanofi-aventis U.S. LLC$1K
- Abbott$909
What the payments were for
- Consulting fees$3,75061%
- Food & beverage$2,42039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zealand Pharma A/s | 1 | $3,750 |
| Amgen | 18 | $405 |
| Astellas Pharma US Inc | 4 | $192 |
| AbbVie(2 entities) | 8 | $173 |
| Novo Nordisk | 9 | $171 |
| Mannkind Corporation | 3 | $165 |
| Amarin Pharma, Inc. | 7 | $128 |
| Pfizer | 6 | $127 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| Boehringer Ingelheim | 4 | $84 |
| Gilead | 3 | $74 |
| Lilly USA, LLC | 4 | $73 |
| Abbott | 3 | $68 |
| Eisai Inc. | 3 | $64 |
| Radius Health, Inc. | 2 | $60 |
| Bausch Health US, LLC | 3 | $55 |
| Medicure Pharma Inc. | 1 | $53 |
| GSK | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Philips North America LLC | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Novartis | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Merck | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Shionogi Inc | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dasiglucagon$3,750
- AFREZZA$131
- MYRBETRIQ$125
How this compares
$6,170 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $28,159 |
| EntrestoSacubitril/Valsartan | 26 | $11,667 |
| Rosuvastatin Calcium | 109 | $3,736 |
| Amiodarone Hcl | 28 | $3,072 |
| Pantoprazole Sodium | 21 | $2,288 |
| SynthroidLevothyroxine Sodium | 21 | $2,234 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,641 |
| Bethanechol Chloride | 13 | $1,502 |
| Memantine Hcl | 18 | $1,482 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,457 |
| ClopidogrelClopidogrel Bisulfate | 20 | $967 |
| Metoprolol Succinate | 50 | $933 |
| Methenamine Hippurate | 11 | $817 |
| Montelukast Sodium | 30 | $787 |
| Duloxetine Hcl | 16 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $73 | $28,15921 claims |
| NovartisEntresto | $22 | $11,66726 claims |
| AbbVieSynthroid | $173 | $2,23421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.